Skip to content
The Nexus
DossierENTITY

GLP-1 agonist

Coverage of GLP-1 agonist in the Nexus archive.

Earliest in view: Jun 8 · 17:00 UTCMost recent: Jun 22 · 16:00 UTC
Co-mentioned in this coverage
berobenatidetopic1American Diabetes Associationorganization1VESPER programorganization1weight losstopic1MedPage Todayorganization1New Orleansplace1obesitytopic1
Recent coverage
  • HEALTHJun 22 · 16:00 UTCMEDPAGE TODAY
    Can Monthly Dosing With Novel GLP-1 Maintain Weight Loss?

    Updated phase II data from the VESPER program showed that patients achieved weight loss with weekly doses of the investigational GLP-1 agonist berobenatide. The study, presented at the American Diabetes Association annual meeting, is exploring whether monthly dosing can maintain these results.

  • HEALTHJun 8 · 17:00 UTCMEDPAGE TODAY
    Monthly GLP-1 for Obesity Promising as More Manageable Alternative

    An ultra-long-acting investigational GLP-1 agonist demonstrated significant weight loss in individuals with overweight or obesity, with continued reductions observed after transitioning to once-monthly dosing.